Company: BIAF
Filing Date: 2025-10-08
Form Type: PRE 14A
Source: 0001493152-25-017460
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-10-08
Form: PRE 14A
Chunk 3
---
                                                                                      
 a later date, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient    
 votes for, or otherwise in connection with, the approval of the Warrant Exercise Proposal, the Warrant Anti-Dilution Adjustment Proposal, 
 the Series B Anti-Dilution Adjustment Proposal and/or the Plan Amendment Proposal (the “Adjournment Proposal”).                           |     | FOR            |     | [●]       |

Even if you plan to attend the Special Meeting, please vote in advance so that your vote will be counted if you later decide not to attend the Special Meeting.

| 1 |

<div align='center'>QUESTIONS AND ANSWERS ABOUT

THE PROXY MATERIALS AND THE SPECIAL MEETING</div>

Who is soliciting my vote?

The Board of Directors of bioAffinity Technologies, Inc. is soliciting your proxy to be used at the Special Meeting.

When and where will the Special Meeting be held?

The Special Meeting will be held on Wednesday, November 11, 2025, at 8:00 a.m. Central Time, at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.

What do I need to do if I would like to attend the Special Meeting?

If you wish to attend the Special Meeting in person, you must present a valid form of photo identification, such as a driver’s license. If you are a beneficial owner of Common Stock that is held of record by a bank, broker, or other nominee, you will also need proof of ownership to be admitted. In this regard, a recent brokerage statement or a letter from your bank or broker are examples of proof of ownership. The Company reserves the right to prohibit cameras, recording equipment, or electronic devices in the Special Meeting.

What am I voting on at the Special Meeting?

The purpose of the Special Meeting is to vote on the following items described in this Proxy Statement:

| Proposal No. 1:                                                                                                                             
 To consider and approve issuance of up to an aggregate of 271,500 shares of our Common Stock upon the exercise of (i) 223,831 shares        
 of our Common Stock issuable upon exercise of Common Stock purchase warrants issued in connection with our private placement offering       
 that closed on August 14, 2025 (the “August 2025 Common Warrants”), (ii) 47,669 shares of our Common Stock                                  
 issuable upon exercise of Common Stock